CAS: 522650-91-5
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | 2-((5-Propyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)-N-(4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)acetamide REF: IN-DA023PTKCAS: 522650-91-5 | 98% | To inquire | Mon 16 Dec 24 |
 | SIRT2-IN-9 REF: TM-T62515CAS: 522650-91-5 | 99.5% | 74.00 €~546.00 € | Mon 03 Feb 25 |
2-((5-Propyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)-N-(4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)acetamide
CAS:522650-91-5
Formula:
C21H22N6OS2
Purity:
98%
Molecular weight:
438.5690
Ref: IN-DA023PTK
| 5mg | 169.00 € | ||
| 10mg | 284.00 € | ||
| 25mg | 506.00 € | ||
| 50mg | To inquire | ||
| 100mg | To inquire |
Estimated delivery in United States, on Monday 16 Dec 2024
SIRT2-IN-9
CAS:522650-91-5
SIRT2-IN-9: selective SIRT2 inhibitor; IC50=1.3μM; halts MCF-7 cell growth; for cancer study.
Formula:
C21H22N6OS2
Purity:
99.5%
Color and Shape:
Liquid
Molecular weight:
438.57
Ref: TM-T62515
| 5mg | 74.00 € | ||
| 10mg | 114.00 € | ||
| 25mg | 230.00 € | ||
| 50mg | 364.00 € | ||
| 100mg | 546.00 € |
Estimated delivery in United States, on Monday 3 Feb 2025
